Medical Marijuana announced that Axim Biotechnologies, a cannabinoid-based product developer in which it owns a strategic interest, has released a product pipeline chart highlighting development timelines for its cannabinoid-based therapeutics, including those for multiple sclerosis (MS) patients.
The chart illustrates the stage each drug is in, from preclinical testing to, eventually, applications for regulatory approval, the diseases and their symptoms that each is meant to treat, and an anticipated market introduction date.
Among the products spotlighted is the first patented cannabinoid controlled-release chewing gum, Med-Chew 1401, to treat pain and spasticity in MS patients. Axim anticipates starting a proof-of-concept Phase 2a clinical trial of the gum next year, and its possible market release in 2018 or 2019.
Other versions of MedChew, a THC/CBD (tetrahydrocannabinol/cannabidiol) controlled-release gum also known as MedChew Rx, aim to treat Parkinson’s, dementia, and a neurological disorder called restless leg syndrome.
“We commend AXIM for publishing a product pipeline chart on its website … about the numerous cannabinoid-based therapeutic products that AXIM currently has undergoing clinical trials and when those products are anticipated to be on the market,” Stuart Titus, Medical Marijuana’s chief executive officer, said in a press release. “It’s exciting to see the actual timelines for these cannabinoid-based innovations currently in development, as we’re confident that once on the market these novel therapeutics will provide consumers with a wide variety of new options worldwide.”
Products also on the chart include Renecann, a series of cannabigerol (CBG)-based skincare products; Oraximax, a series of CBG-based oral care products; Suppocann, a suppository cannabinoid-release product for gastrointestinal conditions like inflammatory bowel syndrome and Crohn’s disease; and Ophthocann and Cannbleph, a pair of cannabinoid-based products to lower intraocular pressure and relieve conjunctivitis.